CTRI/2020/10/028337尚未招募3 期
Sentinel Lymph Node Biopsy in Post Neoadjuvant Chemotherapy Breast Cancer Patients Using Combination of Fluorescein and Blue Dye Versus Blue Dye Alone - A Randomized Controlled Trial - SLNBPNACTFB
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Post NACT, node negative breast cancer patients who are planned for surgery
- •2.Those who are accepted to participate in the study and gives consent
- •3.Between 18 and 90 years of age.
- •4.ECOG performance status 0-1
排除标准
- •1.Prior surgical procedures that have the potential to substantially alter the lymphatic drainage pattern from the primary tumor to the lymph node basin.
- •2.Allergy to fluorescein /methylene blue
- •3.Pregnant or lactating women
- •4.Renal failure / Renal parenchymal disease patients
研究者
相似试验
已完成
3 期
Sentinel lymph node biopsy after neoadjuvant treatment of breast cancer using blue dye, radioisotope, and indocyanine greeocally advanced breast cancer patientsLocally advanced breast cancer patientssentinel lymphnodesSentinel lymph node biopsyindocyanine greenneoadjuvant chemotherapyTCTR20200730003Department of surgery Faculty of medicine Ramathibodi Hospital , Mahidol university , Bangkok , Thai21
已完成
不适用
Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast CancerBreast CancerInvasive Breast CancerNCT00909441Centre hospitalier de l'Université de Montréal (CHUM)153
尚未招募
不适用
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Initially Node Positive Breast Cancer Patients, Could it Omit Axillary Dissection ?Sentinel Lymph NodeNCT06130241Assiut University30
Unknown
不适用
ICG and Blue Dye Guided Sentinel Lymph Node Biopsy in Patients Underwent Neoadjuvant TherapyBreast NeoplasmsNCT02869815Peking University People's Hospital150
尚未招募
不适用
study to validate and compare two techniques of axillary sampling (4 node sampling and low axillary sampling) with sentinel lymph node biopsy (SLNB) in patients suffering from locally advanced breast cancer for they have received neoadjuvant chemotherapy with cN0 axillary lymph node statusCTRI/2019/05/019464Sanjay Gandhi Postgraduate Institute of Medical Sciences